Advertisement

Liposomal Vincristine: The Central Role of Drug Retention in Defining Therapeutically Optimized Anticancer Formulations

  • Nancy L. Boman
  • Pieter R. Cullis
  • Lawrence D. Mayer
  • Marcel B. Bally
  • Murray S. Webb
Part of the Biotechnology Intelligence Unit book series (BIOIU)

Abstract

Vincristine is an alkaloid derived from Vinca rosea that is effective against a wide variety of human carcinomas.1,2 When used in conjunction with corticosteroids, vincristine is the treatment of choice to induce remissions in childhood leukemia. Vincristine is also part of a complex protocol used in the treatment of adult patients with Hodgkin’s disease or non-Hodgkin’s lymphomas. In addition, vincristine has some effectiveness against Wilms’ tumor, neuroblastoma, brain tumors, rhabdomyosarcoma, and carcinomas of the breast and the bladder, as well as the male and female reproductive systems.

Keywords

Drug Release Antitumor Efficacy Drug Release Rate Large Unilamellar Vesicle Drug Retention 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Carter SK, Livingston RB. Plant products in cancer chemotherapy. Cancer Treat Rep 1976; 60a141–1156.Google Scholar
  2. 2.
    Sieber SM, Mead JAR, Adamson RH. Pharmacology of antitumor agents from higher plants. Cancer Treat Rep 1976; 60: 1127–1139.PubMedGoogle Scholar
  3. 3.
    Owellen RJ, Owens AH Jr, Donigian DW. The binding of vincristine, vinblastine, and colchicine to tubulin. Biochem Biophys Res Commun 1972; 47: 685–691.PubMedCrossRefGoogle Scholar
  4. 4.
    Owelien RJ, Hartke CA, Dickerson RM, Hains, FO. Inhibition of tubulin-microtubule polymerization by drugs of the Vinca alkaloid class. Cancer Res 1976; 36: 1499–1502.Google Scholar
  5. 5.
    Jackson DV Jr, Bender RA. Cytotoxic thresholds of vincristine in a murine and a human leukemia cell line in vitro. Cancer Res 1979; 39:4346-4349.Google Scholar
  6. 6.
    Mayer LD, Nayar R, Thies RL, Boman NL, Cullis PR, Bally MB. Identification of vesicle properties which enhance the antitumour activity of liposomal vincristine against murine Limo leukemia. Cancer Chemother Pharmacol 1993; 33: 17–24.Google Scholar
  7. 7.
    Mayer LD, Bally MB, Hope MJ, Cullis PR. Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochim Biophys Acta 1985; 816: 294–302.PubMedCrossRefGoogle Scholar
  8. 8.
    Madden TD, Harrigan PR, Tai LCL, Bally MB, Mayer LD, Redelmeier TE, Loughrey HC, Tilcock CPS, Reinish LW, Cullis PR. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem Phys Lipids 1990; 53: 37–46.PubMedCrossRefGoogle Scholar
  9. 9.
    Vaage J, Donovan D, Mayhew E, Uster P, Woodle, M. Therapy of mouse mammary carcinomas with vincristine and doxorubin encapsulated in sterically stabilized liposomes. Int J Cancer 1993; 54: 959–964.PubMedCrossRefGoogle Scholar
  10. 10.
    Harrigan PR, Wong KF, Redelmeier TE, Wheeler JJ, Cullis PR. Accumulation of doxorubicin and other lipophilic amines into large unilamellar vesicles in response to transmembrane pH gradients. Biochim Biophys Acta 1993; 1149, 329–338.PubMedCrossRefGoogle Scholar
  11. 11.
    Boman NL, Bally MB, Cullis PR, Mayer LD, Webb MS. Encapsulation of vincristine in liposomes reduces its toxicity and improves its anti-tumor efficacy. J Liposome Res 1995; 5: 523–541.CrossRefGoogle Scholar
  12. 12.
    Boman NL, Mayer LD, Cullis PR. Optimization of the retention properties of vincristine in liposomal systems. Biochim Biophys Acta 1993; 1152: 253–258.PubMedCrossRefGoogle Scholar
  13. 13.
    Mayer LD, Bally MB, Loughrey H, Masin D, Cullis PR. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res 1990; 50575–579.Google Scholar
  14. 14.
    Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SL, Lee K-D, Woodle MC, Lasic DD, Redemann C, Martin FJ. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 1991; 88: 11460–11464.PubMedCrossRefGoogle Scholar
  15. 15.
    Mayhew EG, Lasic D, Babbar S, Martin FJ. Pharmacokinetics and antitumor activity of epirubicin encapsulated in long circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid. Int J Cancer 1992; 51: 302–309.PubMedCrossRefGoogle Scholar
  16. 16.
    Allen TM, Mehra T, Hansen C, Chin Y-C. Stealth liposomes: an improved sustained release system for 1–13-D-arabinofuranosylcytosine. Cancer Res 1992; 52: 2431–2439.PubMedGoogle Scholar
  17. 17.
    Bally MB, Nayar R, Masin D, Hope MJ, Cullis PR, Mayer LD. Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochim Biophys Acta 1990; 1023: 133–139.PubMedCrossRefGoogle Scholar
  18. 18.
    Parr MJ, Bally MB, Culls PR. The presence of GM, in liposomes with entrapped doxorubicin does not prevent RES blockade. Biochim Biophys Acta 1993; 1168: 249–252.PubMedCrossRefGoogle Scholar
  19. 19.
    Allen TM, Chonn A. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett 1987; 223: 42–46.PubMedCrossRefGoogle Scholar
  20. 20.
    Allen TM, Hansen C, Rutledge J. Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. Biochim Biophys Acta 1989; 981: 27–35.PubMedCrossRefGoogle Scholar
  21. 21.
    Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 1988; 85: 6949–6953.PubMedCrossRefGoogle Scholar
  22. 22.
    Liu D, Huang L. pH-sensitive, plasma-stable liposomes with relatively prolonged residence in circulation. Biochim Biophys Acta 1990; 1022: 348–354.PubMedCrossRefGoogle Scholar
  23. 23.
    Boman NL, Masin D, Mayer LD, Cullis PR, Bally MB. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res 1994; 54: 2830–2833.Google Scholar
  24. 24.
    Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer 1995; 72: 896–904.PubMedCrossRefGoogle Scholar
  25. 25.
    Mayer LD, Masin D, Nayar R, Boman NL, Bally MB. Pharmacology of liposomal vincristine in mice bearing Lino ascitic and B16/BL6 solid tumors. Br J Cancer 1995; 71: 482–488.PubMedCrossRefGoogle Scholar
  26. 26.
    Mayer LD, Gelmon K, Cullis PR, Boman N, Webb MS, Embree L, Tolcher T, Bally MB. Preclinical and clinical studies with liposomal vincristine. In: Progress in Drug Delivery Systems IV, Biomedical Research Foundation, Tokyo, 1995; 151–161.Google Scholar
  27. 27.
    Allen TM, Newman MS, Woodle MC, Mayhew E, Uster PS. Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes. Int J Cancer 1995; 62: 199–204.PubMedCrossRefGoogle Scholar
  28. 28.
    Loughrey HC, Bally MB, Reinish LW, Cullis PR. The binding of phosphatidylglycerol liposomes to rat platelets is mediated by complement. Thrombosis Haemostasis 1990; 64: 172–176.Google Scholar
  29. 29.
    Reinish LW, Bally MB, Loughrey HC, Cullis PR. Interactions of liposomes and platelets. Thrombosis Haemostasis 1988; 60: 518–523.Google Scholar
  30. 30.
    Namba Y, Sakakibara T, Masada M, Ito F, Oku N. Glucuronate-modified liposomes with prolonged circulation time. Chem Pharm Bull 1990; 38: 1663–1666.PubMedCrossRefGoogle Scholar
  31. 31.
    Oku N, Namba Y, Okada S. Tumor accumulation of novel RES-avoiding liposomes. Biochim Biophys Acta 1992; 1126: 255–260.PubMedCrossRefGoogle Scholar
  32. 32.
    Tokudome Y, Oku N, Doi K, Namba, Y, Okada S. Antitumor activity of vincristine encapsulated in mice bearing Meth A sarcoma. Biochim Biophys Acta 1996; 1279: 70–74.PubMedCrossRefGoogle Scholar
  33. 33.
    Chonn A, Cullis PR, Devine DV. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J Immunol 1991; 146: 4234–4241.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • Nancy L. Boman
  • Pieter R. Cullis
  • Lawrence D. Mayer
  • Marcel B. Bally
  • Murray S. Webb

There are no affiliations available

Personalised recommendations